Screener
Aclaris Therapeutics ACRS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's total liabilities?
- Aclaris Therapeutics (ACRS) reported total liabilities of $55.11M in Q2 2026.
- How has Aclaris Therapeutics's total liabilities changed year-over-year?
- Aclaris Therapeutics's total liabilities decreased by 4.0% year-over-year, from $57.41M to $55.11M.
- What is the long-term trend for Aclaris Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total liabilities has grown at a 11.6% compound annual growth rate (CAGR), from $33.13M to $57.38M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Aclaris Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude